Rasio cepet Cara Therapeutics (CARA)

Cara Therapeutics, Inc. (CARA) bases its operations on the creation of non-cyclical biologics for chronic pruritus, which is confirmed by the current share price plotted on the chart at 1.95. The firm is recognized as an expert in developing unique selective agents that restore patient comfort. However, the failure of tests for its primary oral medication triggered a financial collapse, creating a critical threat of total business liquidation.

The specifics of the biotechnology sector for Cara Therapeutics, Inc. (CARA) necessitate a high cash reserve to mitigate geopolitical risks and component supply chain disruptions. This quick liquidity chart reflects the company's ability to settle short-term debts without liquidating inventory. The metric aggregates cash and accounts receivable, excluding low-liquidity assets from the calculation. The stability of this ratio confirms financial resilience while conducting costly international clinical trials.